Plasma concentration of cytokins involved in lymph-and angiogenesis in diffuse large B-cell lymphoma;Osoczowe stȩż enie cytokin limfo-i angiogennych u chorych na chłoniaka rozlanego z duż ych komórek B

Acta Haematologica Polonica

Volumn 43, Issue 3, 2012, Pages 277-284

  Anna, Wosztyl ^a   Dariusz, Wołowiec ^b   Ewelina, Ziółkowska ^c   Ewa, Robak ^d   Anna, Korycka Wołowiec ^c  

^a Dzia Hematologii wi tokrzyskiego Centrum Onkologii   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d Klinika Dermatologii i Wenerologii Uniwersytetu   (Poland)

Author keywords

Diffuse large B cell lymphoma; KFGF; Lymphangiogenesis; VEGF C; VEGF D; VEGF R3

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; FIBROBLAST GROWTH FACTOR 2; LACTATE DEHYDROGENASE; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT;

EID: 84873041158     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-5814(12)34005-X     Document Type: Article

References (28)

1. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21: 172-4.
2. Tzankov A, Heiss S, Ebner S, et al. Angiogenesis in nodal B-cell lymphomas: a high throughput study. J Clin Pathol. 2007; 60: 476-82.
3. Aref S, Mabed M, Zalata K, Sakrana M, El Askalany H. The interplay between c-myc oncogen expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in Diffuse Large B Cell Lymphoma (DLBCL): Relationship to patient outcome. Leuk Lymphoma 2004; 45: 499-506.
4. Gratzinger D, Zhao S, Marinelli RJ, et al. Microvessel density and expression of vascular endothelial growth factor and receptors on diffuse large-B-cell lymphoma subtypes. Am J Pathol. 2007; 170: 1362-9.
5. Pazgal I, Boycov O, Shpilberg O, Okon E, Bairey O. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007; 48: 2213-20.
6. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25-35.
7. Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res. 2000; 6: 139-46.
8. Wosztyl A, Korycka-Wołowiec A. Angiogeneza i limfangiogeneza oraz ich znaczenie w nieziarniczych chłoniakach złośliwych. Acta Haematol Pol. 2010; 41: 21-33.
9. Arias V, Soares FA. Vascular density (tumor angiogenesis) in non-Hodgkin's lymphoma and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma. 2000; 40: 157-66.
10. Vacca A, Ribatti D, Ruco L. et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79: 965-70.
11. Jørgensen JM, Sørensen F.B, Bendix K, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584-95.
12. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol. 2008; 134: 381-7.
13. Jørgensen JM, Sørensen FB, Bendix K. et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 1647-60.
14. Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. Prognostic significance of angiogenic/lymphangiogenic, antiapoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 2009; 33: 1627-35.
15. Gratzinger D, Zhao S, Tibshirani RJ. et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline- based chemotherapy. Lab Invest. 2008; 88: 38-47.
16. Gratzinger D, Advani R, Zhao S, et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol. 2010; 148: 235-44.
17. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167-72.
18. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334-9.
19. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the sera concentrations of angiogenic growth factors VEGF and bFGF is independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single institution study of 200 patients. Blood 2000; 96: 3712-8.
20. Niitsu N, Okamato M, Nakamine H, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2002; 68: 91-100.
21. Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998-1005.
22. Paydas S, Seydaoglu G, Ergin M, Erdogan S, Yavuz S. The prognostic significance of VEGF-C and VEGF-A in non- Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 366-73.
23. Fukushima N, Satoh T, Sano M, Tokunaga O. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2001; 42: 709-20.
24. Szarvas T, Jäger T, Laszlo V, et al. Circulating Angiostatin, bFGF, and Tie2/TEK Levels and Their Prognostic Impact in Bladder Cancer. Urology. 2012; 80: 737-48.
25. Gora-Tybor J, Jamroziak K, Szmigielska-Kaplon A, et al. Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 50: 62-7.
26. Wołowiec D, Dybko J, Wróbel T, et al. Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm. 2006; 2006: 42394.
27. Giles FJ, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004; 28: 595-604
28. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 1999; 106: 504-9.